Skip to main content

Judge Refuses Defendants’ Plea to Bifurcate PPI Litigation

Judge Refuses Defendants’ Plea to Bifurcate PPI Litigation

Judge Refuses Defendants’ Plea to Bifurcate PPI Litigation

Introduction

The plaintiffs and defendants involved in Proton Pump Inhibitors (PPIs) kidney injury litigation submitted contradicting proposals last month on how to proceed with the multidistrict litigation (MDL) witnessing a growing number of lawsuits. While the defendant PPI manufacturers AstraZeneca Pharmaceuticals LP, Procter & Gamble Co., McKesson Corp., Takeda Pharmaceuticals USA Inc., Novartis Pharmaceuticals Corp., and Pfizer Inc. wanted the cases to be handled in two phases, the plaintiffs wanted a fast-track proceeding leading to a bellwether program with trial dates set for early 2020. In a case management order issued by Judge Cecchi on May 18, the defendant’s request was rejected and the parties were ordered to meet and discuss as per the plan proposed by the plaintiffs.

Both the parties are scheduled to discuss how to proceed with the federal MDL in a status conference on May 24. The next status conference is on June 12 for which both parties are required to submit a status report and an agenda by June 8.

The PPI litigation is centralized in the District of New Jersey as MDL No. 2789 (In Re:  Proton-Pump Inhibitor Products Liability Litigation [No. II]), presided over by Judge Cecchi. Lawsuits mainly involve Nexium, Prilosec, Protonix, Prevacid drugs that were prescribed to treat heartburn and acid reflux in the stomach. About 4,200 product liability cases are filed in this MDL, each lawsuit alleging that the drug makers failed to warn about the fatal side-effects like kidney failure due to prolonged use of PPI.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!